Research programme: radiolabelled PSMA antibody therapeutics - Cytogen

Drug Profile

Research programme: radiolabelled PSMA antibody therapeutics - Cytogen

Alternative Names: LU-177-7E11; Lutetium-177-labelled 7E11 monoclonal antibody; Lutetium-177-labelled PSMA antibody; Research programme: radiolabelled 7E11 antibody - Cytogen; Research programme: radionuclide-labelled PSMA antibody - Cytogen

Latest Information Update: 25 Jun 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytogen Corporation; Dow Chemical
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 31 Dec 2007 This collaboration is still active
  • 05 Dec 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2005) have been added to the adverse events and pharmacokinetics sections
  • 16 May 2005 Cytogen Corporation and DowpharmaSM contract manufacturing services (a business unit of Dow Chemical) have entered into an agreement to co-develop the radiolabelled PSMA antibody for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top